Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)
-
Narrated by:
-
By:
In this episode I discuss bioequivalence testing and how it was developed to support generic drug approvals, but is now a mainstream tool for all of drug development. I discuss the basics of what bioequivalence means, how the studies are designed, and then how to perform the statistical analysis. I end with some examples of how this can be used for both generic drug and innovator drugs to support labeling.
Links discussed in the show:
- FDA Draft Guidance: Statistical Approaches to Establishing Bioequivalence (Dec 2022) – Excellent detail on methods, models, and SAS examples.
- FDA Guidance: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA.
- Article: “Bioequivalence of generic drugs: a simple explanation for clinicians” (Andrade, 2015) – Great for the 80-125% intuition.
- R-script with example BE analysis (Be sure to copy this text into a file and name it "BE-example.R" then you can run it on your local R instance.
- You can connect with Nathan on LinkedIn and send me a message
- Send Nathan a message
- Sign up for Nathan’s newsletter
Copyright Teuscher Solutions LLC
All Rights Reserved
adbl_web_anon_alc_button_suppression_t1
No reviews yet